Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.

Date publication

septembre 2018

Journal

The Lancet. Haematology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier , Pr FEUGIER Pierre

Tous les auteurs :
Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, Haioun C, Tournilhac O, Bouabdallah R, Gabarre J, Lamy T, Cabeçadas J, Becker S, Jardin F, Mounier N, Salles G,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30172345

Résumé

Immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a standard front-line treatment for follicular lymphoma. The combination of lenalidomide and rituximab has shown high efficacy in relapsed or refractory and untreated follicular lymphoma. We aimed to evaluate the safety and activity of the combination of lenalidomide and R-CHOP (R2-CHOP) in previously untreated patients with high burden follicular lymphoma.

Mots clés

Aged, Antibodies, Monoclonal, Murine-Derived, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cyclophosphamide, therapeutic use, Doxorubicin, therapeutic use, Female, Humans, Kaplan-Meier Estimate, Lenalidomide, Lymphoma, Follicular, drug therapy, Male, Middle Aged, Prednisone, therapeutic use, Thalidomide, analogs & derivatives, Tumor Burden, drug effects, Vincristine, therapeutic use

Référence

Lancet Haematol. 2018 Sep;5(9):e403-e410